![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 3
Zeitschriftenartikel
Weiss, Lena 
ORCID: https://orcid.org/0000-0002-8101-3529; Stintzing, Sebastian; Modest, Dominik Paul; Stahler, Arndt; Weikersthal, Ludwig Fischer von; Reinacher-Schick, Anke; Decker, Thomas; Probst, Victoria ORCID: https://orcid.org/0009-0008-8038-7351; Heinrich, Kathrin ORCID: https://orcid.org/0000-0003-3580-2313; Schwaner, Ingo; Kaiser, Florian; Pihusch, Rudolf; Fuchs, Martin; Held, Swantje; Alig, Annabel; Gruenberger, Birgit; Prager, Gerald Werner; Tougeron, David; Taieb, Julien und Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321
(2026):
First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAFV600E-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group).
In: European Journal of Cancer, Bd. 232, 116105
[PDF, 1MB]
ORCID: https://orcid.org/0000-0002-8101-3529; Stintzing, Sebastian; Modest, Dominik Paul; Stahler, Arndt; Weikersthal, Ludwig Fischer von; Reinacher-Schick, Anke; Decker, Thomas; Probst, Victoria ORCID: https://orcid.org/0009-0008-8038-7351; Heinrich, Kathrin ORCID: https://orcid.org/0000-0003-3580-2313; Schwaner, Ingo; Kaiser, Florian; Pihusch, Rudolf; Fuchs, Martin; Held, Swantje; Alig, Annabel; Gruenberger, Birgit; Prager, Gerald Werner; Tougeron, David; Taieb, Julien und Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321
(2026):
First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAFV600E-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group).
In: European Journal of Cancer, Bd. 232, 116105
[PDF, 1MB]
Holch, Julian Walter ORCID: https://orcid.org/0000-0002-4755-0179; Ohnmacht, Alexander J.; Stintzing, Sebastian ORCID: https://orcid.org/0000-0002-3297-5801; Heinrich, Kathrin ORCID: https://orcid.org/0000-0003-3580-2313; Weiss, Lena ORCID: https://orcid.org/0000-0002-8101-3529; Probst, Victoria ORCID: https://orcid.org/0009-0008-8038-7351; Stahler, Arndt ORCID: https://orcid.org/0000-0003-1041-0137; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander ORCID: https://orcid.org/0000-0002-2494-4087; Kaiser, Florian; Heintges, Tobias; Kahl, Christoph; Kullmann, Frank ORCID: https://orcid.org/0000-0001-5575-1010; Link, Hartmut ORCID: https://orcid.org/0000-0002-9659-0265; Höffkes, Heinz-Gert; Moehler, Markus; Modest, Dominik Paul; Menden, Michael P. und Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321
(2. Mai 2025):
FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters.
In: European Journal of Cancer, Bd. 220, 115388
[PDF, 1MB]
ORCID: https://orcid.org/0000-0002-4755-0179; Ohnmacht, Alexander J.; Stintzing, Sebastian ORCID: https://orcid.org/0000-0002-3297-5801; Heinrich, Kathrin ORCID: https://orcid.org/0000-0003-3580-2313; Weiss, Lena ORCID: https://orcid.org/0000-0002-8101-3529; Probst, Victoria ORCID: https://orcid.org/0009-0008-8038-7351; Stahler, Arndt ORCID: https://orcid.org/0000-0003-1041-0137; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kiani, Alexander ORCID: https://orcid.org/0000-0002-2494-4087; Kaiser, Florian; Heintges, Tobias; Kahl, Christoph; Kullmann, Frank ORCID: https://orcid.org/0000-0001-5575-1010; Link, Hartmut ORCID: https://orcid.org/0000-0002-9659-0265; Höffkes, Heinz-Gert; Moehler, Markus; Modest, Dominik Paul; Menden, Michael P. und Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321
(2. Mai 2025):
FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters.
In: European Journal of Cancer, Bd. 220, 115388
[PDF, 1MB]
Zhang, Danmei ORCID: https://orcid.org/0000-0001-6048-4711; Westphalen, Christoph Benedikt; Quante, Michael; Waldschmidt, Dirk T.; Held, Swantje ORCID: https://orcid.org/0000-0002-1344-9056; Kütting, Fabian; Dorman, Klara; Heinrich, Kathrin ORCID: https://orcid.org/0000-0003-3580-2313; Weiss, Lena; Boukovala, Myrto; Haas, Michael; Boeck, Stefan; Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321 und Probst, Victoria
(2024):
Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer. Results of a phase 1b clinical trial.
In: European Journal of Cancer, Bd. 201, 113926
[PDF, 1MB]
ORCID: https://orcid.org/0000-0001-6048-4711; Westphalen, Christoph Benedikt; Quante, Michael; Waldschmidt, Dirk T.; Held, Swantje ORCID: https://orcid.org/0000-0002-1344-9056; Kütting, Fabian; Dorman, Klara; Heinrich, Kathrin ORCID: https://orcid.org/0000-0003-3580-2313; Weiss, Lena; Boukovala, Myrto; Haas, Michael; Boeck, Stefan; Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321 und Probst, Victoria
(2024):
Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer. Results of a phase 1b clinical trial.
In: European Journal of Cancer, Bd. 201, 113926
[PDF, 1MB]